Patent ID: 7939498

Claim:
A method of treatment for preserving or enhancing the function of an organ allograft, wherein the method comprises inducing angiogenesis in a tissue of a subject comprising administering to a subject an effective amount of an SDF-1 analog having a structure selected from the group consisting of: R N -Lys-Pro-Val-Ser-Leu-Ser-Tyr-Arg-Ala-Pro-Phe-Arg-Phe-Phe-[linker]-Leu- Lys-Trp-Ile-Gln-Glu -Tyr-Leu-Glu-Lys-Ala-Leu-Asn-R C (SEQ ID NO:2) and conservatively modified variants thereof; wherein, the underlined residues Lys-Trp-Ile-Gln-Glu form a cyclic portion of the analog; R N is selected from a group consisting of hydrogen, acetyl, poly(ethylene glycol) or a derivative thereof, a glycosaminoglycan, and a biochemical label; R c is selected from a group consisting of a hydroxyl group, amine, amide, poly(ethylene glycol) or a derivative thereof, a glycosaminoglycan, and a biochemical label; and, the linker consists of four amino acids -Xaa 1 -Xaa 2 -Xaa 3 -Xaa 4 -, wherein Xaa 1 , Xaa 2 , Xaa 3 , and Xaa 4 are each independently selected from a group consisting of (a) any natural amino acid, provided that the natural amino acid is not L- or D-Cys, and (b) any non-natural amino acid having the following structure: wherein, R L consists of (i) an alkylene having a backbone consisting of 1 to 14 carbon atoms; or (ii) a group having from 0 to 10 carbon atoms and bearing a positive charge; and wherein, the linker comprises at least one amino acid having a side chain bearing a positive charge and is not tetralysine.